Bortezomib
Inquiry
| Post Date: | Jan 09,2018 |
| Expiry Date: | Jul 08,2018 |
| Detailed Description: |
Cas No. :179324-69-7
Quantity: mass in stockKilograms Specs:white powder Price:negotiable USD Kilograms Payment Method: T/T, Western Union,Moneygram and Bitcoin. Bortezomib (originally PS-341 and marketed as Velcade by Millennium Pharmaceuticals) is the first therapeutic proteasome inhibitor to be tested in humans. The boron atom within bortezomib catalytically binds the active site of the 26S proteasome with high affinity and specificity, thereby resulting in cell cycle arrest and apoptosis. In normal cells, the proteasome is involved in degradation of ubiquitylated proteins that have been tagged for destruction because they are damaged or unneeded by the cell. However, in cancerous cells, proteasome activity degrades pro-apoptotic proteins such as p53 that would normally result in programmed cell death of the dysfunctional cells. Proteasome inhibitors such as bortezomib interrupt this process, resulting in destruction of cancerous cells. Bortezomib is approved in the U.S. for treating relapsed multiple myeloma and mantle cell lymphoma. In multiple myeloma, complete clinical responses have been obtained in patients with otherwise refractory or rapidly advancing diseases. How it works Bortezomib is a type of cancer treatment drug called a proteasome inhibitor. Proteasomes are in cells. They help to break down proteins that the cell doesn't need. Bortezomib blocks the proteasomes so the proteins build up inside the cell. The cell then dies. |
| CAS Registry Number: | 179324-69-7 |
| Synonyms: | ;VELCADE;dpba;[(1r)-3-methyl-1-[[(2s)-1-oxo-3-phenyl-2-[(pyrazinylcarbonyl)amino]propyl]amino]butyl]-boronic acid;VELCADE(BORTEZOMIB);Boronic acid, B-[(1R)-3-methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(2-pyrazinylcarbonyl)amino]propyl]amino]butyl]-;Bortezomib for research;N-[(1S)-1-(dihydroxyboranyl)-3-methylbutyl]-Nalpha-(pyrazin-2-ylcarbonyl)-D-phenylalaninamide;N-[(1R)-1-(dihydroxyboranyl)-3-methylbutyl]-Nalpha-(pyrazin-2-ylcarbonyl)-L-phenylalaninamide;Bortizomib; |
| Molecular Formula: | C19H25BN4O4 |
| Molecular Weight: | 384.2372 |
| Molecular Structure: | 
|
| Company: | Hengyang Desen Biotechnology Co., Ltd. [ China ] |
| Contact: | ava |
| Tel: | 86-18908446905 |
| Fax: | |
| Email: | ava@ycgmp.com |
-
Disclaimer statement:The information and data included above have been realized by the enterprises and compiled by the staff, and are subject to change without notice to you. The Chemnet makes no warranties or representations whatsoever regarding the facticity, accuracy and validity of such information and data. In order to ensure your interest, we suggest you chose the products posted by our gold suppliers or VIP members.
